BR9801008A - Formulação aerossol adequada para terapia, profilaxia ou contenção de infecções da mycobacterium tuberculosis de um pacientes sofrendo de tuberculose - Google Patents

Formulação aerossol adequada para terapia, profilaxia ou contenção de infecções da mycobacterium tuberculosis de um pacientes sofrendo de tuberculose

Info

Publication number
BR9801008A
BR9801008A BR9801008-5A BR9801008A BR9801008A BR 9801008 A BR9801008 A BR 9801008A BR 9801008 A BR9801008 A BR 9801008A BR 9801008 A BR9801008 A BR 9801008A
Authority
BR
Brazil
Prior art keywords
tuberculosis
containment
aerosol formulation
prophylaxis
therapy
Prior art date
Application number
BR9801008-5A
Other languages
English (en)
Inventor
Alan Bruce Montgomery
Original Assignee
Pathogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pathogenesis Corp filed Critical Pathogenesis Corp
Publication of BR9801008A publication Critical patent/BR9801008A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMULAçãO AEROSSOL ADEQUADA PARA TERAPIA, PROFILAXIA OU CONTENçãO DE INFECçõES DA MYCOBACTERIUM TUBERCULOSIS DE UM PACIENTE SOFRENDO DE TUBERCULOSE". Um processo para tratamento, prevenção e contenção de tuberculose aguda e crónica usando-se uma formulação de aerossol de tobramicina concentrada isenta de conservantes, liberando tobramicina ao espaço endobrónquico dos pulmões, incluindo os alvéolos, em um aerossol tendo diâmetro médio de meio de massa predominantemente entre 1 a 5 Á. O processo compreende a administração de tobramicina em concentração de mil a dez mil vezes maior do que a concentração inibitória mínima de Mycobacterium tuberculosis. Um processo para contenção e decréscimo dos períodos de infectuosidade de pacientes de tuberculose, a períodos de tempo mais curtos.
BR9801008-5A 1997-04-02 1998-04-02 Formulação aerossol adequada para terapia, profilaxia ou contenção de infecções da mycobacterium tuberculosis de um pacientes sofrendo de tuberculose BR9801008A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/825,725 US6083922A (en) 1996-04-02 1997-04-02 Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis

Publications (1)

Publication Number Publication Date
BR9801008A true BR9801008A (pt) 2001-03-20

Family

ID=25244769

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9801008-5A BR9801008A (pt) 1997-04-02 1998-04-02 Formulação aerossol adequada para terapia, profilaxia ou contenção de infecções da mycobacterium tuberculosis de um pacientes sofrendo de tuberculose

Country Status (7)

Country Link
US (1) US6083922A (pt)
AR (1) AR011706A1 (pt)
AU (1) AU6469198A (pt)
BR (1) BR9801008A (pt)
IL (1) IL123848A (pt)
WO (1) WO1998043650A1 (pt)
ZA (1) ZA982447B (pt)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
AU2002247280A1 (en) * 2001-03-09 2002-09-24 Antares Pharma, Inc. Ocular drug delivery nebulizer
PT1320355E (pt) * 2001-05-18 2006-08-31 Chiron Corp Sistema para administracao de uma formulacao de tobramicina
AU2007202942B2 (en) * 2001-05-18 2010-05-27 Novartis Ag Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
EP1598059A1 (en) * 2001-05-18 2005-11-23 Chiron Corporation Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
WO2003037365A1 (en) * 2001-11-01 2003-05-08 The Johns Hopkins University Methods and compositions for treating vascular leak using hepatocyte growth factor
AU2003243191B2 (en) 2002-05-02 2007-09-20 President And Fellows Of Harvard College Formulations limiting spread of pulmonary infections
US20050220720A1 (en) * 2002-05-02 2005-10-06 David Edwards Formulations limiting spread of pulmonary infections
US8245708B2 (en) * 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US7607436B2 (en) * 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
ATE501766T1 (de) 2003-05-20 2011-04-15 James F Collins Ophthalmisches arzneimittelabgabesystem
US8545463B2 (en) 2003-05-20 2013-10-01 Optimyst Systems Inc. Ophthalmic fluid reservoir assembly for use with an ophthalmic fluid delivery device
RU2243776C1 (ru) * 2003-07-08 2005-01-10 Новосибирский научно-исследовательский институт туберкулёза (ННИИТ) Способ лечения туберкулеза легких
WO2005037256A2 (de) * 2003-10-15 2005-04-28 Pari Gmbh Flüssige zubereitung enthaltend tobramycin
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
EP2316419B1 (en) * 2004-05-17 2012-07-11 Gilead Sciences, Inc. Aerosolized fosfomycin/tobramycin combination for the treatment of bacterial respiratory infections
US8627821B2 (en) * 2005-01-10 2014-01-14 Pulmatrix, Inc. Method and device for decreasing contamination
EP1888257A1 (en) * 2005-05-05 2008-02-20 Pulmatrix, Inc. Ultrasonic aerosol generator
EP1901749B1 (en) 2005-05-18 2016-08-03 Raptor Pharmaceuticals Inc. Aerosolized fluoroquinolones and uses thereof
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
EP2402001A1 (en) * 2005-05-18 2012-01-04 Pulmatrix, Inc. Formulations for alteration of biophysical properties of mucosal lining
MX348936B (es) 2005-09-29 2017-07-03 Nektar Therapeutics Formulaciones de antibioticos, dosis unitarias, equipos y metodos.
WO2007145704A2 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
EP2061772A4 (en) 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
JP2008199905A (ja) * 2007-02-16 2008-09-04 Snow Brand Milk Prod Co Ltd 乳酸菌生残性向上剤
JP2012505223A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 薬物動態の改善のためのエアゾールフルオロキノロン配合物
EP2346509B1 (en) 2008-10-07 2020-05-13 Horizon Orphan LLC Inhalation of levofloxacin for reducing lung inflammation
KR101411889B1 (ko) 2009-02-27 2014-06-27 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스 억제제
LT2445502T (lt) 2009-06-25 2017-09-25 Alkermes Pharma Ireland Limited Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui
US20110014273A1 (en) * 2009-07-15 2011-01-20 Helmut Brunar Method of Treating BCC
RU2563809C2 (ru) 2009-09-04 2015-09-20 Мпекс Фармасьютикалс, Инк. Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза
WO2011084846A1 (en) 2010-01-07 2011-07-14 Alkermes, Inc. Quaternary ammonium salt prodrugs
AU2011270701B2 (en) 2010-06-24 2015-05-14 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
EP2593056B1 (en) 2010-07-15 2020-10-21 Eyenovia, Inc. Drop generating device
WO2012009696A2 (en) 2010-07-15 2012-01-19 Corinthian Ophthalmic, Inc. Ophthalmic drug delivery
JP2013531548A (ja) 2010-07-15 2013-08-08 コリンシアン オフサルミック，インコーポレイティド 遠隔治療及び遠隔モニタリングを実施する方法及びシステム
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
RU2017144619A (ru) 2010-09-29 2019-02-20 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
EP3470057B1 (en) 2010-09-29 2021-11-03 Pulmatrix Operating Company, Inc. Cationic dry powders comprising magnesium salt
JP6013364B2 (ja) 2010-12-23 2016-10-25 アルカーメス ファーマ アイルランド リミテッド マルチプルａｐｉローディングプロドラッグ
TWI574687B (zh) 2011-01-03 2017-03-21 古利斯股份有限公司 具有鋅結合部份之刺蝟拮抗劑
JP6021117B2 (ja) 2011-01-31 2016-11-02 ジェノア ファーマシューティカルズ，インク． エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用
DK3111938T3 (da) 2011-04-01 2019-07-01 Curis Inc Phosphoinositid 3-kinase-hæmmer med en zink-bindende gruppe
US20130172830A1 (en) 2011-12-12 2013-07-04 Corinthian Ophthalmic, Inc. Ejector mechanism, ejector device, and methods of use
AU2012351805B2 (en) 2011-12-15 2016-04-21 Alkermes Pharma Ireland Limited Samidorphan (ALKS 33) in combination with opioid agonists
NZ722096A (en) 2011-12-15 2016-11-25 Alkermes Pharma Ireland Ltd Prodrugs of secondary amine compounds
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
JP6501264B2 (ja) 2012-07-24 2019-04-17 アヴァリン ファーマ インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
EP2968285A4 (en) 2013-03-13 2016-12-21 Flatley Discovery Lab COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
JP6473738B2 (ja) 2013-04-01 2019-02-20 パルマトリックス，インコーポレイテッド チオトロピウム乾燥粉末
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
NZ760541A (en) 2014-01-10 2022-08-26 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
SG11201607772WA (en) 2014-03-31 2016-10-28 Debiopharm Int Sa Fgfr fusions
CN106794243A (zh) 2014-08-26 2017-05-31 哈斯福制药公司 新型免疫剂及其使用方法
AU2015328307B2 (en) 2014-10-06 2019-11-21 Apm Therapeutics 1, Inc. Triazolopyridine compounds and methods for the treatment of cystic fibrosis
JP6904970B2 (ja) 2016-03-07 2021-07-21 エナンタ ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎抗ウイルス剤
EP3512602B1 (en) 2016-09-16 2024-03-27 HSF Pharmaceuticals Inhibitors of heat shock factors (hsf) and uses thereof
JP7227163B2 (ja) 2017-06-10 2023-02-21 アイノビア，インコーポレイティド 流体を取扱い、目に流体を送出するための方法および装置
US10952978B2 (en) 2017-08-28 2021-03-23 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2019110099A1 (en) 2017-12-06 2019-06-13 Qrumpharma Inc. Inhalable clofazimine formulation
US20210401968A1 (en) 2018-03-08 2021-12-30 Hsf Pharmaceuticals Sa Localized activation of virus replicatio boosts herpesvirus-vectored vaccines
US20210128735A1 (en) 2018-05-10 2021-05-06 Cis Pharma Ag Biocompatible copolymer containing multiple active agent molecules
KR102834026B1 (ko) 2018-08-23 2025-07-14 맨카인드 코포레이션 클로파지민의 조성물, 이들을 포함하는 조합물, 이들의 제조 방법, 이들을 포함하는 용도 및 방법
SG11202102343QA (en) 2018-09-11 2021-04-29 Curis Inc Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
UY38383A (es) 2018-09-21 2020-04-30 Enanta Pharm Inc Heterociclos funcionalizados como agentes antivirales
EP3653716A1 (en) 2018-11-19 2020-05-20 HSF Pharmaceuticals Replication-competent controlled alpha-herpesvirus virus vectors and uses therefore
BR112021023832A8 (pt) 2019-06-04 2023-02-28 Thirty Holdings Ltd Métodos e composições para geração de óxido nítrico e usos dos mesmos
BR112021023632A2 (pt) 2019-06-04 2022-04-19 Thirty Respiratory Ltd Métodos e composições para gerar óxido nítrico e usos do mesmo para entregar óxido nítrico através do trato respiratório
CN114641316A (zh) 2019-10-30 2022-06-17 Cis制药股份公司 用于递送活性剂的生物相容性聚合物药物载体
WO2021113795A1 (en) 2019-12-05 2021-06-10 Flatley Discovery Lab, Llc Compounds and methods for the treatment of cystic fibrosis
WO2021119513A1 (en) 2019-12-11 2021-06-17 Eyenovia, Inc. Systems and devices for delivering fluids to the eye and methods of use
JP2023526583A (ja) 2020-04-23 2023-06-22 サーティー レスピラトリー リミテッド 結核を治療及び抑制するための方法及び組成物
US20240016831A1 (en) 2020-04-23 2024-01-18 Thirty Respiratory Limited Nitric oxide or nitric oxide releasing compositions for use in treating sars-cov and sars-cov-2
WO2021214279A1 (en) 2020-04-24 2021-10-28 Hsf Pharmaceuticals Replication-competent controlled herpesviruses expressing a sars cov-2 antigen
CA3185481A1 (en) 2020-06-01 2021-12-09 Advent Therapeutics, Inc. Pharmaceutical compositions comprising insoluble active ingredients
WO2021262799A1 (en) 2020-06-23 2021-12-30 Flagship Pioneering, Inc. Anti-viral compounds and methods of using same
GB2607514B (en) 2020-07-20 2023-06-21 Enanta Pharm Inc Functionalized peptides as antiviral agents
IL302991A (en) 2020-11-23 2023-07-01 Enanta Pharm Inc Antivirals that are derivatives of the novel spiropyrrolidine
WO2022240897A1 (en) 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung
WO2023006993A1 (en) 2021-07-30 2023-02-02 Atmosr Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome
WO2023028364A1 (en) 2021-08-27 2023-03-02 Sepelo Therapeutics, Llc Targeted compositions and uses therof
WO2025214935A1 (en) 2024-04-11 2025-10-16 Hsf Pharmaceuticals Sa Recombinant alphaherpesvirus vectors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5284133A (en) * 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization

Also Published As

Publication number Publication date
IL123848A0 (en) 1998-10-30
US6083922A (en) 2000-07-04
IL123848A (en) 2002-12-01
AR011706A1 (es) 2000-08-30
AU6469198A (en) 1998-10-22
WO1998043650A1 (en) 1998-10-08
ZA982447B (en) 1999-01-26

Similar Documents

Publication Publication Date Title
BR9801008A (pt) Formulação aerossol adequada para terapia, profilaxia ou contenção de infecções da mycobacterium tuberculosis de um pacientes sofrendo de tuberculose
ES2168302T3 (es) Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e.
CA2301723A1 (en) Butyrate derivatives in the treatment of fibromyalgia and chronic fatigue syndrome
NO972475L (no) Ny antitrombotisk formulering, fremgangsmåte for dens fremstilling og anvendelse derav
BR0315868A (pt) Método para tratar ou melhorar infecção pulmonar em um paciente portador de fibrose cìstica; e método para tratar ou melhorar infecção pulmonar em um animal
BR9916296A (pt) Método para tratamento de bronquite crÈnica severa (bronquiectase) com um antibiótico em forma de aerossol
NO944565D0 (no) Preparat med regulert frigjörelse som inneholder et morfinsalt
DE69518334D1 (de) Pharmazeutische aerosol welche mindestens ein zucker enthält
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
DK0630230T3 (da) Farmaceutiske inhaleringspræparater
CA2240717A1 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
BR9709838A (pt) Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
EE9700302A (et) Meetod maania ja bipolaarse häire raviks
CA2120062A1 (en) Use of Sulodexide and of Medicines Containing It in the Treatment of Diabetic Nephropathy
KR950701820A (ko) 패혈증 및 패혈증-연관 옹고장애의 예방 및 치료(prophylaxs and treatment of sepsis and sepsis-associated coagulation disorders)
NO964915L (no) Transdermal avlevering av antiepileptiske legemidler
Arnes et al. A comparison between middle and inferior meatal antrostomy in the treatment of chronic maxillary sinus infection
DK0615443T3 (da) Lægemiddel i akut virksom form indeholdende Flurbiprofen og anvendelse deraf
BR9813641A (pt) "preparados transmucosais de levosimendan"
CA2216789A1 (en) Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers
BR9713514A (pt) Novo uso de creatina
AU3733295A (en) Treatment of obstructive airway disease by administering thymosin beta 4, or coadministration of thymosin beta 4 and dnase i
NZ307601A (en) Use of a pharmaceutically acceptable oxalate derivative in the manufacture of a medicament for the treatment of skin conditions
RU95100741A (ru) Способ лечения туберкулеза легких
CO4600680A1 (es) Procedimientos para la prevencion de la degradacion de la proteina c

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: REFERENTE A RPI 1924 DE 20/11/2007.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO DISPOSTO NOS ARTIGOS 8O, 11 E 13 DA LPI 9.279/96.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 9/00 (2006.01), A61K 31/7036 (2006.0